Federica Piana
Dr. Piana and colleagues comment on the low sensitivity of the tuberculin skin test (TST) in patients with active tuberculosis as reported in our study, which examined routine use of the new interferon-␥ (IFN-␥) QuantiFERON-TB Gold (Cellestis Ltd., Carnegie, Victoria, Australia) test for the diagnosis of tuberculosis infection (1) . They also compare the 33.3% rate of positive TST in our report with the 87.0% rate of positive TST that they observed among 46 patients with tuberculosis in an unpublished study. Further, they highlight the special characteristics of our inpatients with active disease. In fact, out of the 11 patients with tuberculosis, 4 had extrapulmonary or disseminated disease while three others had concomitant cancer or were taking immunosuppressive drugs; all these medical conditions are known to significantly reduce the rate of positive TST results (2, 3) . Moreover, the low proportion of patients with positive microbiology results was also due to the significant fraction of cases with extrapulmonary localization or with concomitant immunosuppression.
Piana and colleagues also refer to the results of a contact tracing investigation among 138 immunosuppressed patients in a hematology unit, where they used the T-SPOT.TB test (Oxford Immunotec Ltd.) to detect infected contacts (4) . In that study, they identified 35 contacts who were positive with T-SPOT.TB and negative with the TST, thus suggesting a higher sensitivity of T-SPOT.TB. These results are consistent with recent reports on the use of T-SPOT.TB (5, 6) , showing high sensitivity for the diagnosis of tuberculosis infection in immunosuppressed patients. This does not seem to be the case with the QuantiFERON-TB Gold test used in our study, as we observed a high proportion of indeterminate results, which were strongly associated with immunosuppression (1).
As discussed in our article, at the present time, only data from preselected cohorts of patients have been published for QuantiFERON-TB Gold. QuantiFERON-TB Gold (a whole blood test based on the ELISA technique) and T-SPOT.TB (using the ELISPOT technology on preseparated blood cells) have some methodological differences (7) . Only the ELISPOT test has been used in those patients in whom the TST is most often falsely negative, such as HIV-infected patients (6) and newborns (8) . Data in these vulnerable groups are lacking for QuantiFERON-TB Gold, and direct comparative studies of both blood tests in parallel have not yet been published. Therefore, in our paper, we focus on the rate of indeterminate results of the QuantiFERON-TB Gold in patients routinely tested for tuberculosis infection in a hospital setting. We did not infer any conclusions regarding the other commercially available test.
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Adult Hospital and Ventilator-associated Pneumonia Guidelines: Eminence-rather than Evidence-based
To the Editor :
We read with interest the guidelines on the management of adult hospital and ventilator-associated pneumonia issued by the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) (1). However, we were disappointed by the subsection entitled "Modulation of colonization." The guidelines confirm that the oropharynx is the major source of potential pathogens that cause lower airway infections, an observation made by Johanson more than 30 years ago (2) . Eradication of aerobic gram-negative bacilli (AGNB) carriage with chlorhexidine mouthwashes is a new message. In the randomized controlled trial (RCT) of DeRiso and colleagues (3), potential pathogens were not identified, although it is well known that AGNB, in particular Pseudomonas aeruginosa and Acinetobacter baumannii, are intrinsically resistant to chlorhexidine. A recent English RCT failed to confirm the DeRiso study (4) .
We would like to make it quite clear that oropharyngeal decontamination on its own has never been shown to reduce mortality (5) , and that the ATS/IDSA Guideline Committee is misleading the readers in mentioning the two individual RCTs of large sample size showing an absolute mortality reduction of 8% under the heading of oral decontamination. These two RCTs evaluated oral and gut decontamination using enteral and parenteral antimicrobials, which is quite different from only oropharyngeal decontamination. Those two RCTs were included in the most recent meta-analysis of 36 RCTs of selective decontamination of the digestive tract (SDD) showing a significant relative mortality reduction of 22% (odds ratio [OR], 0.78; 95% confidence interval [CI], 0.68-0.89) (6) . Unfortunately, the committee did not mention this meta-analysis, while meta-analyses were commonly included in the guidelines for other maneuvers.
A proper resistance analysis should distinguish multiresistant AGNB, methicillin-resistant Staphylococcus aureus (MRSA), from vancomycin-resistant enterococci (VRE). In a Parisian intensive care unit (ICU) with high endemic levels of Klebsiella pneumoniae producing extended spectrum ␤-lactamase (ESBL), SDD cleared the resistant outbreak strain in a randomized design (7) . Similarly, 5 years of SDD in an Innsbruck ICU rendered the unit free from multiresistant AGNB (8) . In an observational study in a Manchester unit with endemicity of ESBL-producing Klebsiella, SDD given to all patients cleared the outbreak strain within 3 months (9). Therefore, SDD did not increase the AGNB resistance problem but solved the problem of endemicity of multiresistant AGNB.
Fair enough. SDD, by design, is not active against MRSA, and seven SDD RCTs undertaken in units with MRSA endemicity show a trend toward a higher MRSA infection rate (10-16). Under these circumstances, enteral vancomycin must be added to the classical polymyxin/tobramycin/amphotericin B (PTA) protocol (17). Two American RCTs evaluated PTA in an ICU setting with VRE endemicity, and reported the same carriage and infection rates in both groups (18, 19). Eight RCTs assessed SDD, including enteral vancomycin, and VRE problems did not emerge (17, (20) (21) (22) (23) (24) (25) (26) . Three ecology studies demonstrated that the introduction of new potent antimicrobials, such as piperacillin/ tazobactam, which disregard the ICU patient's normal flora, promoted VRE, while enteral vancomycin, given to treat Clostridium difficile in a VRE environment, did not promote VRE (27-29). Antimicrobial resistance, being a long-term issue, has been evaluated in eight SDD studies: bacterial resistance associated with SDD has not been a clinical problem (30-37). The recommendation of the ATS/IDSA Guideline Committee that routine SDD should be discouraged because of resistance is expert opinion and not supported by evidence.
